# Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis

> **NCT05863936** · PHASE3 · UNKNOWN · sponsor: **Nanjing University School of Medicine** · enrollment: 15 (estimated)

## Conditions studied

- Lupus Nephritis
- Remission
- Safety Issues

## Interventions

- **DRUG:** Methylprednisolone Injectable Suspension
- **DRUG:** Belimumab Injection
- **DRUG:** Immunosuppressive Agents

## Key facts

- **NCT ID:** NCT05863936
- **Lead sponsor:** Nanjing University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863936, "Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05863936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*